These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20176717)

  • 21. Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.
    Al Therwani S; Rosenbæk JB; Mose FH; Bech JN; Pedersen EB
    BMC Nephrol; 2017 Mar; 18(1):86. PubMed ID: 28288570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study.
    van der Zander K; Houben AJ; Hofstra L; Kroon AA; de Leeuw PW
    Am J Physiol Heart Circ Physiol; 2003 Sep; 285(3):H1206-12. PubMed ID: 12738624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation.
    Boerrigter G; Costello-Boerrigter LC; Harty GJ; Lapp H; Burnett JC
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R897-901. PubMed ID: 17068158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
    McKie PM; Cataliotti A; Ichiki T; Sangaralingham SJ; Chen HH; Burnett JC
    J Am Heart Assoc; 2014 Jan; 3(1):e000206. PubMed ID: 24385449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
    Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
    J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide.
    Nishizaki Y; Yamagami S; Sesoko M; Yamashita H; Daida H
    J Cardiol Cases; 2013 Nov; 8(5):151-154. PubMed ID: 30546768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction.
    Sica D; Oren RM; Gottwald MD; Mills RM;
    Clin Cardiol; 2010 Jun; 33(6):330-6. PubMed ID: 20556802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2008 Jul; 1(2):134-42. PubMed ID: 19808282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
    Christ M; Ludwig N; Maisch B
    Herz; 2002 Mar; 27(2):135-49. PubMed ID: 12025459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'.
    Verbrugge FH; Dupont M; Steels P; Grieten L; Swennen Q; Tang WH; Mullens W
    Eur J Heart Fail; 2014 Feb; 16(2):133-42. PubMed ID: 24464967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
    J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Horton DP; Burnett JC
    J Card Fail; 2004 Apr; 10(2):115-9. PubMed ID: 15101022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
    Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
    J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention.
    La Villa G; Riccardi D; Lazzeri C; Casini Raggi V; Dello Sbarba A; Tosti Guerra C; Fronzaroli C; Foschi M; Laffi G; Gentilini P
    Hepatology; 1995 Dec; 22(6):1745-50. PubMed ID: 7489983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
    Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
    Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.